TY - JOUR T1 - Antimicrobial activity of tigecycline against bacterial isolates from intensive care units in a teaching hospital in Central Saudi Arabia JF - Saudi Medical Journal JO - Saudi Med J SP - 18 LP - 24 VL - 31 IS - 1 AU - Ali M. Somily AU - Abdulaziz S. Al-Khattaf AU - Abdelmageed M. Kambal Y1 - 2010/01/01 UR - http://smj.org.sa/content/31/1/18.abstract N2 - OBJECTIVE: To test the activity of tigecycline against bacterial isolates including multi-drug resistant (MDR) gram negative and gram positive organisms from intensive care patients.METHODS: Clinically significant gram positive and MDR gram negative isolates from specimens of patients in the intensive care units of King Khalid University Hospital (KKUH), Riyadh, Kingdom of Saudi Arbia between November 1, 2006 and December 31, 2008 were tested against tigecycline by disc diffusion (DD) method. In some isolates, the minimal inhibitory concentration was carried out by E-test method. Some of the gram negative isolates, and gram positive isolates were tested using both methods. The study was approved by the hospital ethics committee.RESULTS: All the 83 gram positive organisms tested by both DD and E-test were susceptible to tigecycline. Two hundred and fifty-four MDR gram negative isolates were tested for susceptibility to tigecycline. Of these 176 tested by DD, 159 (90%) were susceptible, 6 (3.4%) were resistant, and 11 (6.2%) were intermediately susceptible (data are not the same in table 3). From the 188 isolates tested by E-test, 140 (74.4%) were susceptible, 35 (18.6%) were resistant, and 13 (6.9%) showed intermediate susceptibility. For comparison between the methods, 109 isolates of the MDR gram negative organisms were tested by both E test and DD. The difference between the 2 methods was not significant.CONCLUSION: Tigecycline was active against gram positive and most MDR gram negative isolates from patients in medical and surgical intensive cases in KKUH. There was no significant difference between the DD and E-test methods for susceptibility testing of tigecycline against these isolates. ER -